Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer

Tumor Biology

Volumn 37, Issue 3, 2016, Pages 4127-4134

  Cui, Di ^a   Yu, Cai Hua ^b   Liu, Min ^c   Xia, Qing Qing ^a   Zhang, Yu Feng ^a   Jiang, Wei Long ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HUZHOU CENTRAL HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Non small cell lung cancer; Proliferation; PVT1

Indexed keywords

LONG UNTRANSLATED RNA; PROTEIN P15; PROTEIN P21; PVT1 LONG-NON-CODING RNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MTT ASSAY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PVT1 GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; UPREGULATION; YOUDEN INDEX; AREA UNDER THE CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, LONG NONCODING; ROC CURVE;

EID: 84944930171     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4261-x     Document Type: Article

References (14)

1. Bunn Jr PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004;6:85–98.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
3. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.
4. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.
5. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.
6. Tu ZQ, Li RJ, Mei JZ, Li XH. Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7:4303–9.
7. Yan TH, Lu SW, Huang YQ, Que GB, Chen JH, Chen YP, et al. Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer. Tumour Biol. 2014;35:10249–57.
8. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013;190:2278–87.
9. Colombo T, Farina L, Macino G, Paci P. PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int. 2015;2015:304208.
10. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014;60:1278–90.
11. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, et al. Amplification of PVT1is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2013;110:164–71.
12. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007;13:5745–55.
13. Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079–93.
14. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149–63.